Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells

Blood

Volumn 108, Issue 4, 2006, Pages 1284-1290

  Levy, Ofer ^b   Suter, Eugénie E ^c   Miller, Richard L ^a   Wessels, Michael R ^c  

^a 3M COMPANY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; I KAPPA B ALPHA; IMIDAZOQUINOLINE DERIVATIVE; INTERLEUKIN 12; LIPOPEPTIDE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; RESIQUIMOD; S (2,3 DIS ACYLOXYPROPYL) CYSTEINE GLYCYLASPARAGYLASPARAGYLASPARTYLGLUTAMINYLSERYLASPARAGYLISOLEUCYLSERYLPHENYLALANYLLYSYLGLUTAMINYLLYSINE; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NEWBORN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TH1 CELL; UPREGULATION;

EID: 33747201640     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-12-4821     Document Type: Article

References (47)

1. Klein J, Remington J. Current concepts of infections of the fetus and newborn infant. In: Remington J, Klein J, eds. Infectious Diseases of the Fetus and Newborn Infant. 5th ed. Philadelphia, PA: WB Saunders; 2001:1-23.
2. WHO. The World Health Report. Geneva, Switzerland: World Health Organization; 2005.
3. Lambert PH. Vaccines for the world: major challenges for the future. Southeast Asian J Trop Med Public Health. 1997;28(suppl 2):122-126.
4. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile [see comment]. JAMA. 1999;281:1520-1527.
5. Adkins B. Development of neonatal Th1/Th2 function. Int Rev Immunol. 2000;19:157-171.
6. Makhseed M, Raghupathy R, Azizieh F, Omu A, Al-Shamali E, Ashkanani L. Th1 and Th2 cytokine profiles in recurrent aborters with successful pregnancy and with subsequent abortions. Human Reprod. 2001;16:2219-2226.
7. El-Harith el HA. The cytokine TNF-alpha. Genetics and suitability for prenatal risks assessment. Saudi Med J. 2004;25:135-140.
8. Marchant A, Goetghebuer T, Ota MO, et al. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. J Immunol. 1999;163:2249-2255.
9. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
10. Steinman RM, Inaba K. Myeloid dendritic cells. J Leukoc Biol. 1999;66:205-208.
11. Gill MA, Palucka AK, Barton T, et al. Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. J Infect Dis. 2005;191:1105-1115.
12. Trinchieri G. Interleukin-12. In: Gallin JI, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:505-512.
13. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111-135.
14. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004;22:307-328.
15. Goriely S, Van Lint C, Dadkhah R, et al. A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells. J Exp Med. 2004;199:1011-1016.
16. Chelvarajan RL, Collins SM, Doubinskaia IE, et al. Defective macrophage function in neonates and its impact on unresponsiveness of neonates to polysaccharide antigens. J Leukoc Biol. 2004;75:982-994.
17. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol. 2004;4:499-511.
18. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216.
19. Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw. 2000;11:362-371.
20. Chuang TH, Ulevitch RJ. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw. 2000;11:372-378.
21. Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23:165-175.
22. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 [see comment]. Science. 2004;303:1526-1529.
23. Philbin VJ, Iqbal M, Boyd Y, et al. Identification and characterization of a functional, alternatively spliced Toll-like receptor 7 (TLR7) and genomic disruption of TLR8 in chickens. Immunology. 2005;114:507-521.
24. Hemmi H, Kaisho T, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway [comment]. Nat Immunol. 2002;3:196-200.
25. Heil F, Ahmad-Nejad P, Hemmi H, et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003;33:2987-2997.
26. Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005;174:1259-1268.
27. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529-1531.
28. Triantafilou K, Orthopoulos G, Vakakis E, et al. Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell Microbiol. 2005;7:1117-1126.
29. Jefferies CA, Doyle S, Brunner C, et al. Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem. 2003;278:26258-26264.
30. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168:4531-4537.
31. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines. 2003;2:219-229.
32. Levy O, Zarember KA, Roy RM, Cywes C, Godowski PJ, Wessels MR. Selective impairment of Toll-like receptor-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod but preserves response to R-848. J Immunol. 2004;173:4627-4634.
33. Galanos C, Gumenscheimer M, Muhlradt P, Jirillo E, Freudenberg M. MALP-2, a Mycoplasma lipopeptide with classical endotoxic properties: end of an era of LPS monopoly? J Endotoxin Res. 2000;6:471-476.
34. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999;162:3749-3752.
35. Jurk M, Heil F, Vollmer J, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 [comment]. Nat Immunol. 2002;3:499.
36. Martin TR, Ruzinski JT, Wilson CB, Skerrett SJ. Effects of endotoxin in the lungs of neonatal rats: age-dependent impairment of the inflammatory response. J Infect Dis. 1995;171:134-144.
37. Cohen L, Haziot A, Shen DR, et al. CD14-independent responses to LPS require a serum factor that is absent from neonates. J Immunol. 1995;155:5337-5342.
38. De Wit D, Tonon S, Olislagers V, et al. Impaired responses to toll-like receptor 4 and toll-like receptor 3 ligands in human cord blood. J Autoimmun. 2003;21:277-281.
39. Kaisho T, Akira S. Regulation of dendritic cell function through Toll-like receptors. Curr Mol Med. 2003;3:373-385.
40. Zhu W, Downey JS, Gu J, Di Padova F, Gram H, Han J. Regulation of TNF expression by multiple mitogen-activated protein kinase pathways. J Immunol. 2000;164:6349-6358.
41. Kuprash DV, Udalova IA, Turetskaya RL, Kwiatkowski D, Rice NR, Nedospasov SA. Similarities and differences between human and murine TNF promoters in their response to lipopolysaccharide. J Immunol. 1999;162:4045-4052.
42. Becker C, Wirtz S, Ma X, Blessing M, Galle PR, Neurath MF. Regulation of IL-12 p40 promoter activity in primary human monocytes: roles of NF-kappaB, CCAAT/enhancer-binding protein beta, and PU.1 and identification of a novel repressor element (GA-12) that responds to IL-4 and prostaglandin E(2). J Immunol. 2001;167:2608-2618.
43. Qin H, Wilson CA, Lee SJ, Zhao X, Benveniste EN. LPS induces CD40 gene expression through the activation of NF-{kappa}B and STAT-1{alpha} in macrophages and microglia. Blood. 2005;106:3114-3122.
44. Yan SR, Qing G, Byers DM, Stadnyk AW, Al-Hertani W, Bortolussi R. Role of MyD88 in diminished tumor necrosis factor alpha production by newborn mononuclear cells in response to lipopolysaccharide. Infect Immun. 2004;72:1223-1229.
45. + T cell responses. J Immunol. 2005;174:7676-7683.
46. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, Wessels MR. The adenosine system selectively inhibits TLR-mediated TNF-α production in human newborn. J Immunol. 2006. In press.
47. Angelone DF, Wessels MR, Coughlin M, et al. Innate immunity of the human newborn is polarized towards a high ratio of IL-6/TNF-α production in vitro and in vivo. Ped Res. 2006;60:1-5.